Director/PDMR Shareholding

RNS Number : 3414F

Novacyt S.A.

13 November 2020

 

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK - 13 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 13 November 2020, James McCarthy (PDMR), a corporate consultant, acquired 10,000 ordinary shares of €1/15 each in the Company at an average price of £8.953 per share.  The resultant beneficial shareholding of Mr McCarthy is 10,000 ordinary shares representing 0.01% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	James McCarthy
2.	Reason for the Notification
a)	Position/status	Corporate consultant and classified as a PDMR of the Company
b)	Initial notification/ Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Novacyt S.A.
b)	LEI	213800BWAC2BF295EG28
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each
	Identification code	FR0010397232
b)	Nature of the transaction	Acquisition of Ordinary Shares
c)	Price(s) and volume(s)	Price Volume £8.848 1,130 £8.931 4,478 £9.001 4,320 £9.073 72
d)	Aggregated information: · Aggregated volume · Price	Price Volume £8.953 10,000
e)	Date of the transaction	13 November 2020
f)	Place of the transaction	London Stock Exchange, AIM

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

[phone]

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

[phone]

[e-mail] ; [e-mail]

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

[phone]

[e-mail] / [e-mail]  

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]  

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests.  Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing.  The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide.  The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

 

END

 

 

DSHGPGMAGUPUGMW